This work was supported by Grant MMH-9657 from the Mackay Memorial Hospital in Taipei (Taiwan).
Anti-“Mia” immunization is associated with HLA-DRB1*0901
Article first published online: 12 NOV 2008
© 2009 American Association of Blood Banks
Volume 49, Issue 3, pages 472–478, March 2009
How to Cite
Chu, C.-C., Ho, H.-T., Lee, H.-L., Chan, Y.-S., Chang, F.-J., Wang, C.-L. and Lin, M. (2009), Anti-“Mia” immunization is associated with HLA-DRB1*0901. Transfusion, 49: 472–478. doi: 10.1111/j.1537-2995.2008.01976.x
- Issue published online: 13 FEB 2009
- Article first published online: 12 NOV 2008
- Received for publication May 28, 2008; revision received July 20, 2008; and accepted September 2, 2008.
BACKGROUND: Anti-“Mia” is one of the most important irregular red blood cell antibodies found in Taiwan. The aim of this study was to investigate whether specific HLA-DRB1 alleles are associated with anti-“Mia” production.
STUDY DESIGN AND METHODS: A case-control retrospective study was performed on 68 patients showing presence of anti-“Mia” and 219 unrelated control subjects from the Mackay Memorial Hospital. HLA-DRB1 genotyping was carried out using sequence-based typing method. Fisher's exact test using 2 × 2 contingency tables was used to analyze significance of the association between DRB1 polymorphisms and presence of anti-“Mia” in patients.
RESULTS: HLA-DRB1*0901 allele frequency in the anti-“Mia” group (30%) was significantly higher than in the control group (16%) with an odds ratio of 2.27 (95% confidence interval, 1.44-3.55; p = 0.0005; pc = 0.016).
CONCLUSION: HLA-DRB1*0901 is significantly more prevalent in the anti-“Mia” patients group than in the control group. It is suggested that cells from DR9 individuals might present processed “Mia” antigen-allospecific peptides more effectively than cells from individuals carrying other DR phenotypes. Finally, it was predicted that two epitopes, derived from the MiIII glycophorin amino acid sequence, were likely to bind preferentially with the DR9 molecule. Further work will be necessary to determine if these epitopes are responsible for anti-“Mia” alloimmunization.